Auriga hires sales and marketing executive Andrew Shales to lead product launches

By E. Janene Geiss

Philadelphia, Jan. 4 - Auriga Laboratories, Inc. announced Wednesday that Andrew D. Shales has been named senior vice president of sales and marketing.

Shales, a pharmaceutical industry executive with nearly 20 years of experience in leading and coordinating pharmaceutical sales and marketing activities, has joined the senior management team of Auriga, according to a company news release.

He has an impressive track record for commercializing pharmaceutical products, building commercial teams, strategic planning, product launch implementation and opinion leader development, officials said.

At Auriga, Shales will be leading a national sales force and marketing initiative dedicated to promoting the company's prescription product portfolio.

"We are very pleased to add a sales and marketing executive of Mr. Shales' caliber to the Auriga management team as we look toward new product launches in 2006," Guy Amato, Auriga chief executive officer, said in the release.

Most recently, Shales was vice president of sales and marketing for Synthon Pharmaceuticals, Inc., a development-based company specializing in Abbreviated New Drug Applications and 505 (b)(2) New Drug Applications.

Prior to this, Shales was marketing leader at First Horizon Pharmaceutical Corp., an acquisition-driven specialty pharmaceutical company with net revenues of $115 million.

Auriga said it also recently elected Philip P. Pesin, an executive with extensive experience in establishing innovative companies in the pharmaceutical and other industries, as chairman of the board.

Auriga is a Norcross, Ga., specialty pharmaceutical company that develops and markets new prescription products for approved drugs using proprietary drug delivery technologies and reformulation strategies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.